Lumena raises $23M to advance liver-disease drug

05/9/2013 | American City Business Journals

A Series A funding round has brought in $23 million to Lumena Pharmaceuticals, a California-based biotech firm founded by Pappas Ventures. Proceeds will go toward the development of the company's lead drug candidate for cholestatic liver disease. Lumena plans to conduct midstage trials of the drug in adults with primary biliary cirrhosis and in children with alagille syndrome and progressive familial intrahepatic cholestasis.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Abbott
Santa Clara, CA
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA